Virax Biolabs Group Limited (VRAX) Return on Equity ROE from the fourth quarter 2024 to fourth quarter and annually, average high and low, overall ranking from Mar 31 2024 to - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Virax Biolabs Group Limited  (NASDAQ: VRAX)

Virax Biolabs Group Limited's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Virax Biolabs Group Limited in the fourth quarter 2024?


Within the In Vitro & In Vivo Diagnostic Substances industry 10 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2024 from 0 to 3868.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2024)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter
Y / Y Equity Change 6.29 % -42.29 % - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions 0 0 0 0 0
Return On Equity (TTM) 0 % 0 % 0 % 0 % 0 %
VRAX's Total Ranking # 3868 # 0 # 0 # 0 #
Equity (TTM) in Millions 5 5 9 5 5
Seq. Equity Change 6.29 % -42.29 % 73.27 % 0 % -42.29 %
Seq. Net Income Change - - - - -

Back to VRAX Management Effectiveness >> VRAX's 5 Years Annual ROE >> Compare VRAX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 11
Sector # 644
Overall # 3868

Return On Equity Statistics
High Average Low
-61.3 %
-101.17 %
-131.14 %
(Mar 31 2023)   (Mar 31 2024)





VRAX Annual Return On Equity (Mar 31 2025)
2025		 (Mar 31 2024)
2024		 (Mar 31 2023)
2023		 (Mar 31 2021)
2022
Total Equity in Millions 5 5 9 -1 0
Y / Y Equity Change 6.29 % -42.29 % - - -
Net Income in Millions -6 -7 -5 -2 0
Y / Y Net Income Change - - - - -
Return On Equity -111.08 % -131.14 % -61.3 % - -

Back to VRAX Management Effectiveness >> VRAX's 5 Years Annual ROE >> Compare VRAX ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
VRAX's' Return on Equity at Yahoo Finance
VRAX's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for VRAX's Competitors
Subscribers only: Roe for Virax Biolabs Group Limited's Suppliers
Subscribers only: Return On Equity for VRAX's Customers




Companies with similar Return On Equity at Mar 31 2024, within Healthcare Sector ROE

Date modified: 2024-10-22T17:06:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.